Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.

Spring MD, Sousa JC, Li Q, Darko CA, Morrison MN, Marcsisin SR, Mills KT, Potter BM, Paolino KM, Twomey PS, Moon JE, Tosh DM, Cicatelli SB, Froude JW, Pybus BS, Oliver TG, McCarthy WF, Waters NC, Smith PL, Reichard GA, Bennett JW.

J Infect Dis. 2019 Sep 24. pii: jiz386. doi: 10.1093/infdis/jiz386. [Epub ahead of print]

PMID:
31549155
2.

MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.

Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Büttner R, Sen T, Byers LA, Reinhardt HC, Letai A, Oliver TG, Sos ML.

Nat Commun. 2019 Aug 2;10(1):3485. doi: 10.1038/s41467-019-11371-x.

3.

Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF.

Nat Rev Cancer. 2019 Jul;19(7):415. doi: 10.1038/s41568-019-0164-2.

PMID:
31175338
4.

MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.

Chalishazar MD, Wait SJ, Huang F, Ireland AS, Mukhopadhyay A, Lee Y, Schuman SS, Guthrie MR, Berrett KC, Vahrenkamp JM, Hu Z, Kudla M, Modzelewska K, Wang G, Ingolia NT, Gertz J, Lum DH, Cosulich SC, Bomalaski JS, DeBerardinis RJ, Oliver TG.

Clin Cancer Res. 2019 Aug 15;25(16):5107-5121. doi: 10.1158/1078-0432.CCR-18-4140. Epub 2019 Jun 4.

PMID:
31164374
5.

Partners in Crime: Neutrophil-CTC Collusion in Metastasis.

Guo B, Oliver TG.

Trends Immunol. 2019 Jul;40(7):556-559. doi: 10.1016/j.it.2019.04.009. Epub 2019 May 15.

PMID:
31101536
6.

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF.

Nat Rev Cancer. 2019 May;19(5):289-297. doi: 10.1038/s41568-019-0133-9. Review. Erratum in: Nat Rev Cancer. 2019 Jun 7;:.

PMID:
30926931
7.

The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment.

Mollaoglu G, Jones A, Wait SJ, Mukhopadhyay A, Jeong S, Arya R, Camolotto SA, Mosbruger TL, Stubben CJ, Conley CJ, Bhutkar A, Vahrenkamp JM, Berrett KC, Cessna MH, Lane TE, Witt BL, Salama ME, Gertz J, Jones KB, Snyder EL, Oliver TG.

Immunity. 2018 Oct 16;49(4):764-779.e9. doi: 10.1016/j.immuni.2018.09.020.

8.

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.

Wagner AH, Devarakonda S, Skidmore ZL, Krysiak K, Ramu A, Trani L, Kunisaki J, Masood A, Waqar SN, Spies NC, Morgensztern D, Waligorski J, Ponce J, Fulton RS, Maggi LB Jr, Weber JD, Watson MA, O'Conor CJ, Ritter JH, Olsen RR, Cheng H, Mukhopadhyay A, Can I, Cessna MH, Oliver TG, Mardis ER, Wilson RK, Griffith M, Griffith OL, Govindan R.

Nat Commun. 2018 Sep 17;9(1):3787. doi: 10.1038/s41467-018-06162-9.

9.

Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers.

Huang F, Ni M, Chalishazar MD, Huffman KE, Kim J, Cai L, Shi X, Cai F, Zacharias LG, Ireland AS, Li K, Gu W, Kaushik AK, Liu X, Gazdar AF, Oliver TG, Minna JD, Hu Z, DeBerardinis RJ.

Cell Metab. 2018 Sep 4;28(3):369-382.e5. doi: 10.1016/j.cmet.2018.06.005. Epub 2018 Jun 28.

10.

Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.

Zhang W, Girard L, Zhang YA, Haruki T, Papari-Zareei M, Stastny V, Ghayee HK, Pacak K, Oliver TG, Minna JD, Gazdar AF.

Transl Lung Cancer Res. 2018 Feb;7(1):32-49. doi: 10.21037/tlcr.2018.02.02.

11.

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.

Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, Oliver TG, Heymach JV, Glisson BS, Wang J, Byers LA.

Oncotarget. 2017 Sep 1;8(43):73419-73432. doi: 10.18632/oncotarget.20621. eCollection 2017 Sep 26.

12.

Family matters: How MYC family oncogenes impact small cell lung cancer.

Brägelmann J, Böhm S, Guthrie MR, Mollaoglu G, Oliver TG, Sos ML.

Cell Cycle. 2017 Aug 18;16(16):1489-1498. doi: 10.1080/15384101.2017.1339849. Epub 2017 Jul 24. Review.

13.

MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

Mollaoglu G, Guthrie MR, Böhm S, Brägelmann J, Can I, Ballieu PM, Marx A, George J, Heinen C, Chalishazar MD, Cheng H, Ireland AS, Denning KE, Mukhopadhyay A, Vahrenkamp JM, Berrett KC, Mosbruger TL, Wang J, Kohan JL, Salama ME, Witt BL, Peifer M, Thomas RK, Gertz J, Johnson JE, Gazdar AF, Wechsler-Reya RJ, Sos ML, Oliver TG.

Cancer Cell. 2017 Feb 13;31(2):270-285. doi: 10.1016/j.ccell.2016.12.005. Epub 2017 Jan 12.

14.

Mighty mouse breakthroughs: a Sox2-driven model for squamous cell lung cancer.

Mukhopadhyay A, Oliver TG.

Mol Cell Oncol. 2014 Nov 11;2(2):e969651. doi: 10.4161/23723548.2014.969651. eCollection 2015 Apr-Jun.

15.

Squamous non-small cell lung cancer as a distinct clinical entity.

Oliver TG, Patel J, Akerley W.

Am J Clin Oncol. 2015 Apr;38(2):220-6. doi: 10.1097/COC.0b013e3182a0e850. Review.

PMID:
25806712
16.

Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo.

Terry MR, Arya R, Mukhopadhyay A, Berrett KC, Clair PM, Witt B, Salama ME, Bhutkar A, Oliver TG.

Cell Death Differ. 2015 May;22(5):719-30. doi: 10.1038/cdd.2014.159. Epub 2014 Oct 10.

17.

GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer.

Masin M, Vazquez J, Rossi S, Groeneveld S, Samson N, Schwalie PC, Deplancke B, Frawley LE, Gouttenoire J, Moradpour D, Oliver TG, Meylan E.

Cancer Metab. 2014 Jul 29;2:11. doi: 10.1186/2049-3002-2-11. eCollection 2014.

18.

Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer.

Mukhopadhyay A, Berrett KC, Kc U, Clair PM, Pop SM, Carr SR, Witt BL, Oliver TG.

Cell Rep. 2014 Jul 10;8(1):40-9. doi: 10.1016/j.celrep.2014.05.036. Epub 2014 Jun 19.

19.

Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction.

Curry NL, Mino-Kenudson M, Oliver TG, Yilmaz OH, Yilmaz VO, Moon JY, Jacks T, Sabatini DM, Kalaany NY.

Cancer Discov. 2013 Aug;3(8):908-21. doi: 10.1158/2159-8290.CD-12-0507. Epub 2013 May 29.

20.

Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.

Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, Jacks T.

Cancer Discov. 2011 Aug;1(3):236-47. doi: 10.1158/2159-8290.CD-11-0073. Epub 2011 Jun 16.

21.

Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop.

Oliver TG, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ, Hubbard D, Bhutkar A, Jacks T.

Mol Cell. 2011 Jul 8;43(1):57-71. doi: 10.1016/j.molcel.2011.06.012.

22.

Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy.

Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT.

Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20786-91. doi: 10.1073/pnas.1011409107. Epub 2010 Nov 10.

23.

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.

Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, Thomale J, Jacks T, Sweet-Cordero EA.

Genes Dev. 2010 Apr 15;24(8):837-52. doi: 10.1101/gad.1897010.

24.

Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis.

Schliekelman M, Cowley DO, O'Quinn R, Oliver TG, Lu L, Salmon ED, Van Dyke T.

Cancer Res. 2009 Jan 1;69(1):45-54. doi: 10.1158/0008-5472.CAN-07-6330.

25.

Aurora-A kinase is essential for bipolar spindle formation and early development.

Cowley DO, Rivera-Pérez JA, Schliekelman M, He YJ, Oliver TG, Lu L, O'Quinn R, Salmon ED, Magnuson T, Van Dyke T.

Mol Cell Biol. 2009 Feb;29(4):1059-71. doi: 10.1128/MCB.01062-08. Epub 2008 Dec 15.

26.

The use of positron emission tomography-computed tomography scan in the evaluation of a patient with Carney complex.

Bandelin PB, Moreno AJ, Lemar HJ, Stratakis CA, Oliver TG.

J Clin Endocrinol Metab. 2008 Aug;93(8):2946-7. doi: 10.1210/jc.2008-0313. No abstract available.

27.

Fibroblast growth factor blocks Sonic hedgehog signaling in neuronal precursors and tumor cells.

Fogarty MP, Emmenegger BA, Grasfeder LL, Oliver TG, Wechsler-Reya RJ.

Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2973-8. Epub 2007 Feb 13.

28.

Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma.

Oliver TG, Read TA, Kessler JD, Mehmeti A, Wells JF, Huynh TT, Lin SM, Wechsler-Reya RJ.

Development. 2005 May;132(10):2425-39. Epub 2005 Apr 20.

29.

Getting at the root and stem of brain tumors.

Oliver TG, Wechsler-Reya RJ.

Neuron. 2004 Jun 24;42(6):885-8. Review.

30.

Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors.

Oliver TG, Grasfeder LL, Carroll AL, Kaiser C, Gillingham CL, Lin SM, Wickramasinghe R, Scott MP, Wechsler-Reya RJ.

Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7331-6. Epub 2003 May 30.

31.

The post hospital: past to present.

Oliver TG.

Mil Med. 1990 Dec;155(12):613-7.

PMID:
2125344
32.

Education brought to life with summer internships.

Oliver TG, Oliver PR.

Provider. 1987 May;13(5):50-1. No abstract available.

PMID:
10312051
33.

The establishment of a sickle cell program in the college and community health setting.

Oliver TG, Glenn L, Anthony JL, Edwards CY.

J Am Coll Health. 1986 Jun;34(6):290-1. No abstract available.

PMID:
3745696
34.

Sharing health services: two universities, a seminary, and a community.

Oliver TG, Oliver PR, Anthony JL.

J Am Coll Health. 1985 Dec;34(3):138-9. No abstract available.

PMID:
4086720
35.

Operating a health facility during difficult times.

Oliver TG.

Hosp Top. 1984 Nov-Dec;62(6):25. No abstract available.

PMID:
10278284
36.

Job Corps, Missouri facility team to train nursing assistants.

Oliver TG, Oliver P.

Contemp Adm Long Term Care. 1983 Aug;6(8):38. No abstract available.

PMID:
10295279
37.

Hospital fills a radiotherapy void through sharing.

Oliver TG.

Hosp Top. 1983 May-Jun;61(3):16-7. No abstract available.

PMID:
10259482
38.

Subterranean building aids in the conservation of energy and related costs.

Oliver TG.

Hosp Top. 1982 Nov-Dec;60(6):22-3. No abstract available.

PMID:
10257461
39.

Interior design brings light into subterranean radiation center.

Oliver TG.

Hospitals. 1981 Oct 16;55(20):95, 98. No abstract available.

PMID:
7275090
40.

The radiation therapy chart: a clinical chart for a radiation therapy center.

Oliver TG.

J Am Med Rec Assoc. 1980 Dec;51(6):102-3. No abstract available.

PMID:
10249008

Supplemental Content

Loading ...
Support Center